Omeprazole, widen of Cmax in a normal crossover design? [Design Issues]

posted by wienui  – Germany/Oman, 2016-04-07 13:00 (3717 d 18:11 ago) – Posting: # 16169
Views: 8,981

❝ ❝ “The primary pharmacokinetic variables evaluated for single dose studies were AUC0-t and Cmax and for steady state, AUCτ and Cmax. Bioequivalence was determined based on limits of 80-125% for AUC and 70-143% for Cmax.”


Dear All,

Could we widen the Cmax rang to 70-143% of HVD (Omeprazole) in a normal (not a replicate) 2x2 crossover BE study.

Thanks,

Cheers,
Osama

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
140 visitors (0 registered, 140 guests [including 20 identified bots]).
Forum time: 07:12 CEST (Europe/Vienna)

Outside his own ever-narrowing field of specialization,
a scientist is a layman.
What members of an academy of science have in common
is a certain form of semiparasitic living.    Erwin Chargaff

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5